Key facts
| Price (PPV) | 306 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | amlodipinevalsartan |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DB01 |
| Manufacturer | AFRIC-PHAR |
| Presentation | Boite de 56 |
| Nature | Médicament |
| Hospital price | 204 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de l'hypertension artérielle essentielle. L’association amlodipine-valsartan est indiquée chez les patients dont la tension artérielle est insuffisamment contrôlée par le valsartan seul ou par l'amlodipine seule. L’association amlodipine-valsartan est indiquée pour le traitement initial de l'hypertension artérielle. La décision de prescrire L’association amlodipine-valsartan en traitement initial de l'hypertension artérielle doit reposer sur une évaluation des bénéfices et des risques potentiels.
Find an open pharmacy
On-call pharmacies near you
About Suliat 5 mg | 160 mg
Suliat 5 mg | 160 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by AFRIC-PHAR and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Suliat 5 mg | 160 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Suliat 5 mg | 160 mg
Answers to common questions from Moroccan patients about this drug.